Conflict of interest All authors have contributed to the conception and design, to the analysis and interpretation of data, to the drafting of the article. All authors have revised the manuscript critically for important intellectual content and have approved the version to be published.
Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management
Version of Record online: 28 APR 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 27, Issue 1, pages 11–18, January 2013
How to Cite
Manousaridis, I., Mavridou, S., Goerdt, S., Leverkus, M. and Utikal, J. (2013), Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management. Journal of the European Academy of Dermatology and Venereology, 27: 11–18. doi: 10.1111/j.1468-3083.2012.04546.x
- Issue online: 18 DEC 2012
- Version of Record online: 28 APR 2012
- Received: 27 December 2011; Accepted: 26 March 2012
Table S1. CTCAE Grading of relevant skin tissue disorders (CTCAE = Common Terminology Criteria for Adverse Events, version 4.0; ADL = activities of daily living; BSA = body surface area; IV = intravenous).
|JDV_4546_sm_TableS1.docx||17K||Supporting info item|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.